Therapy Areas: AIDS & HIV
Stallergenes Greer partners with Alyatec to advance precision medicine in allergen immunotherapy
12 July 2021 -

London's healthcare company Stallergenes Greer on Friday announced plans to advance precision medicine in AIT (allergen immunotherapy) under a research collaboration with Alyatec, a contract research organisation based in Strasbourg University Hospital, France.

Through this partnership with Alyatec, Stallergenes Greer will strengthen its precision medicine-based approach and the management of patients with allergies by expanding its knowledge of allergy pathophysiology and endotypes, AIT mode of action and clinical validation.

The research collaboration will combine the longstanding expertise of Stallergenes Greer in AIT with Alyatec's competencies in research and clinical services as well as its state-of-the-art technology, including a new generation environmental exposure chamber.

Allergies are reportedly the most prevalent and fastest growing chronic disease in the industrialised world, affecting over one billion people worldwide. Allergen immunotherapy is an allergy treatment designed to alter the natural course of respiratory allergies by treating the underlying cause of the disease. Allergen extracts are modifying disease by inducing tolerance in the immune system.

Login
Username:

Password: